Seegene, Inc.

KOSDAQ:A096530 Stock Report

Market Cap: ₩1.1t

Seegene Past Earnings Performance

Past criteria checks 1/6

Seegene's earnings have been declining at an average annual rate of -22.6%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been declining at an average rate of 3.4% per year. Seegene's return on equity is 2.9%, and it has net margins of 7.4%.

Key information

-22.6%

Earnings growth rate

-22.3%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-3.4%
Return on equity2.9%
Net Margin7.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Nov 22
Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Recent updates

Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Jan 08
Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Nov 22
Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings

Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Nov 12
Is Seegene (KOSDAQ:096530) Using Too Much Debt?

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Aug 10
Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07
A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06
Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15
I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?

Feb 25
Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?

Seegene (KOSDAQ:096530) Is Growing Earnings But Are They A Good Guide?

Feb 08
Seegene (KOSDAQ:096530) Is Growing Earnings But Are They A Good Guide?

What Is The Ownership Structure Like For Seegene, Inc. (KOSDAQ:096530)?

Jan 22
What Is The Ownership Structure Like For Seegene, Inc. (KOSDAQ:096530)?

Calculating The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Jan 07
Calculating The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23
Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08
Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Revenue & Expenses Breakdown

How Seegene makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A096530 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24399,42229,472148,29370,922
30 Jun 24382,48423,128146,65673,868
31 Mar 24367,272-3,461140,92772,659
31 Dec 23367,375669138,06772,733
30 Sep 23389,688-2,578140,08575,008
30 Jun 23448,646-8,971152,70576,267
31 Mar 23492,15918,719163,66184,725
31 Dec 22853,561182,139190,84594,738
30 Sep 221,140,776343,230232,75397,173
30 Jun 221,295,241447,057237,63398,026
31 Mar 221,470,535537,404247,84490,520
31 Dec 211,370,833536,559240,95575,539
30 Sep 211,402,531559,365226,09963,951
30 Jun 211,424,097618,128204,15350,622
31 Mar 211,395,194633,289179,97637,764
31 Dec 201,125,216502,281140,58125,948
30 Sep 20717,254321,43786,60817,948
30 Jun 20421,777175,80963,58713,483
31 Mar 20176,24555,32445,54510,359
31 Dec 19121,95326,67239,6119,647
30 Sep 19118,44526,67640,2929,542
30 Jun 19110,40223,17639,4469,352
31 Mar 19105,86114,30439,3069,341
31 Dec 18102,26510,09839,73610,277
30 Sep 1897,9755,95140,58510,514
30 Jun 1894,6844,97239,81111,671
31 Mar 1891,9794,68437,27215,094
31 Dec 1788,9203,69335,62612,603
30 Sep 1783,0926,56833,74710,834
30 Jun 1780,8174,64433,3028,407
31 Mar 1777,2855,67233,6743,396
31 Dec 1673,6947,12333,8263,434
30 Sep 1670,5192,82732,6123,206
30 Jun 1667,9736,36732,7373,001
31 Mar 1665,9036,28931,6022,708
31 Dec 1565,1376,77430,6652,630
30 Sep 1563,8349,20430,2822,569
30 Jun 1563,5388,62028,9342,426
31 Mar 1563,8078,41228,5352,538
31 Dec 1464,4119,14128,4162,812
30 Sep 1465,0298,02127,8172,976
30 Jun 1465,1418,06727,0083,070
31 Mar 1462,5959,41426,3922,994

Quality Earnings: A096530 has a large one-off gain of ₩15.9B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A096530 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A096530's earnings have declined by 22.6% per year over the past 5 years.

Accelerating Growth: A096530 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A096530 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A096530's Return on Equity (2.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 08:59
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Seegene, Inc. is covered by 19 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mujinn LeeCape Investment & Securities Co., Ltd.
David LeeCLSA
Jinhee KwakEugene Investment & Securities Co Ltd.